NCT02038179View on ClinicalTrials.gov

Center of Research Translation (CORT) Project 2

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Pre-hypertensionJNC 7 Stage I Hypertension
Interventions
DRUG

Allopurinol

Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.

DRUG

Placebo

Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT02038179 - Center of Research Translation (CORT) Project 2 | Biotech Hunter | Biotech Hunter